What do systematic reviews say?

Intervention not reported

The intervention showed no clear difference in normal versus simulated altitude conditions: risk of AMS (low certainty).

• Interventions for preventing high altitude illness: Part 3. Miscellaneous and non‐pharmacological interventions 2019 · Cochrane Headline outcomes only
  RR 1.18 [0.82, 1.71]
  3 studies · 140 participants
  Low

Intervention not reported

The intervention may leads to higher positive end‐expiratory pressure (PEEP) versus nothing: risk of AMS (low certainty).

• Interventions for preventing high altitude illness: Part 3. Miscellaneous and non‐pharmacological interventions 2019 · Cochrane Headline outcomes only
  OR 3.67 [1.38, 9.76]
  1 study · 8 participants
  Low

Intervention not reported

The intervention showed no clear difference in remote ischaemic preconditioning (RIPC) versus placebo: risk of AMS (low certainty).

• Interventions for preventing high altitude illness: Part 3. Miscellaneous and non‐pharmacological interventions 2019 · Cochrane Headline outcomes only
  RR 3 [0.69, 13.12]
  1 study · 40 participants
  Low

Intervention not reported

The review found no eligible studies for this question.

• Interventions for preventing high altitude illness: Part 3. Miscellaneous and non‐pharmacological interventions 2019 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Intervention not reported

The intervention showed no clear difference in antioxidants versus placebo: risk of AMS (low certainty).

• Interventions for preventing high altitude illness: Part 3. Miscellaneous and non‐pharmacological interventions 2019 · Cochrane Headline outcomes only
  RR 0.58 [0.32, 1.03]
  1 study · 18 participants
  Low

Intervention not reported

The intervention may leads to lower ginkgo biloba versus placebo: risk of AMS (low certainty).

• Interventions for preventing high altitude illness: Part 3. Miscellaneous and non‐pharmacological interventions 2019 · Cochrane Headline outcomes only
  no estimate extracted
  6 studies · 504 participants
  Low

Intervention not reported

It is very uncertain whether the intervention changes erythropoietin versus placebo: risk of AMS (very low certainty).

• Interventions for preventing high altitude illness: Part 3. Miscellaneous and non‐pharmacological interventions 2019 · Cochrane Headline outcomes only
  RR 0.41 [0.2, 0.84]
  1 study · 39 participants
  Very low

Intervention not reported

The intervention showed no clear difference in medroxyprogesterone versus placebo: risk of AMS (low certainty).

• Interventions for preventing high altitude illness: Part 3. Miscellaneous and non‐pharmacological interventions 2019 · Cochrane Headline outcomes only
  RR 0.71 [0.48, 1.05]
  2 studies · 32 participants
  Low

Intervention not reported

The review found no eligible studies for this question.

• Interventions for treating acute high altitude illness 2018 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Intervention not reported

The review found no eligible studies for this question.

• Interventions for treating acute high altitude illness 2018 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Intervention not reported

The review found no eligible studies for this question.

• Interventions for treating acute high altitude illness 2018 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Intervention not reported

• Interventions for treating acute high altitude illness 2018 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 64 participants
  Low

Intervention not reported

• Interventions for treating acute high altitude illness 2018 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 29 participants
  Low

Intervention not reported

The review found no eligible studies for this question.

• Interventions for treating acute high altitude illness 2018 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Intervention not reported

• Interventions for treating acute high altitude illness 2018 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 35 participants
  Low

Intervention not reported

The intervention showed no clear difference in reduction in symptom score severity Time of measurement: 1 to 48… (low certainty).

• Interventions for treating acute high altitude illness 2018 · Cochrane Headline outcomes only
  Mean Difference 1.15
  2 studies · 25 participants
  Low

Intervention not reported

• Interventions for treating acute high altitude illness 2018 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 25 participants
  Low

Sumatriptan vs placebo

Sumatriptan may leads to lower risk of acute mountain sickness compared with placebo (low certainty).

• Interventions for preventing high altitude illness: Part 2. Less commonly‐used drugs 2018 · Cochrane Headline outcomes only
  RR 0.43 [0.21, 0.84]
  1 study · 102 participants
  Low

Spironolactone vs placebo

The review found no eligible studies for this question.

• Interventions for preventing high altitude illness: Part 2. Less commonly‐used drugs 2018 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Acetazolamide vs spironolactone 100 mg

Acetazolamide may leads to lower risk of acute mountain sickness compared with spironolactone (low certainty).

• Interventions for preventing high altitude illness: Part 2. Less commonly‐used drugs 2018 · Cochrane Headline outcomes only
  RR 0.36 [0.18, 0.7]
  1 study · 232 participants
  Low